

FIG. 1

Patient no.	Sex <sup>a</sup>	Antiretroviral regimen <sup>b</sup>		Mo of HAART	CD4 cell count (cells/ $\mu$ l)	Plasma viral load (log <sub>10</sub> eq copies/ml)
		Initial	Modification (mo <sup>c</sup> )			
1	M	Naive		247	4.85	
2	M	Naive		262	4.62	
3	F	Naive		302	4.24	
4	M	Naive		374	5.14	
5	M	Naive		395	4.88	
6	M	Naive		415	4.21	
7	F	Naive		421	4.38	
8	M	Naive		467	5.22	
9	F	Naive		541	4.39	
10	M	Naive		557	5.01	
11	M	3TC-d4T-IDV	None	40	<1.70	
12	M	3TC-d4T-IDV	None	42	<1.70	
13	F	3TC-d4T-IDV	None	40	<1.70	
14	M	3TC-d4T-IDV	None	38	<1.70	
15	M	3TC-d4T-IDV	None	41	<1.70	
16	F	3TC-d4T-IDV	3TC-ZDV-IDV (1)	38	559	<1.70
17	M	3TC-d4T-IDV	3TC-ZDV-IDV (5)	43	566	<1.70
18	F	3TC-d4T-IDV	None	38	605	<1.70
19	M	3TC-d4T-IDV	None	40	612	<1.70
20	M	3TC-d4T-IDV	None	40	696	<1.70
21	M	3TC-d4T-IDV	None	39	311	5.44
22	M	3TC-d4T-IDV	3TC-ZDV-IDV (4)	41	385	4.26
23	M	3TC-d4T-IDV	3TC-d4T-RTV-SQV (6)	43	397	4.79
24	M	3TC-d4T-IDV	None	45	401	4.28
25	M	3TC-d4T-IDV	3TC-d4T-RTV-SQV (8)	42	409	5.87
26	M	3TC-d4T-IDV	3TC-d4T-RTV-SQV (8)	42	523	4.67
27	M	3TC-d4T-IDV	None	41	569	5.63
28	F	3TC-d4T-IDV	3TC-d4T-RTV-SQV (7)	44	646	5.18
29	M	3TC-d4T-IDV	3TC-ZDV-IDV (5)	42	654	4.47
30	M	3TC-d4T-IDV	3TC-ZDV-IDV (4)	41	672	5.15

<sup>a</sup> M, male; F, female.<sup>b</sup> ZDV, zidovudine; 3TC, lamivudine; d4T, stavudine; IDV, indinavir; RTV, ritonavir; SQV, saquinavir.<sup>c</sup> Indicates the time after which the initial antiretroviral regimen was modified because of side effects of IDV or d4T.

FIG. 2A





FIG. 2B

FIG. 3A





FIG. 3B

FIG. 4B

Log HIV RNA copies/ml of culture supernatant   Log proviral HIV DNA copies/million of PBMC




FIG. 4A




FIG. 4D




FIG. 4C




FIG. 5A




FIG. 5B




FIG. 5C



FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D

FIG. 7A





FIG. 7B

FIG. 7C




FIG. 7D




FIG. 7E





FIG. 7F




FIG. 8A




FIG. 8B




FIG. 8C



FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B

Animal no.	Sex	Weight (kg)	CD4 <sup>+</sup> T cells/ $\mu$ l		Plasma SIV RNA log <sub>10</sub> copies/ml		Immunization
			Day 0	Day 60	Peak (day 14)	Set point (day 60)	
<b>Group A</b>							
1	male	4.5	958	1172	7.99	5.31	AT-2-inactivated
2	male	4.7	1151	803	7.83	5.27	SIV-loaded DC
3	male	4.8	900	1192	7.02	5.70	vaccine at weeks
4	male	4.8	2316	906	7.09	5.71	0, 2, 4, 6, and 8
5	male	4.4	995	1081	6.95	5.22	
6	female	4.6	797	803	7.80	5.29	
7	female	5.2	1061	834	7.69	5.91	
8	female	5.0	1124	1267	7.46	5.27	
9	female	4.6	1092	918	8.13	5.14	
10	female	5.0	760	961	7.60	5.48	
Mean		4.8	1115	1034	7.56	5.43	
s.d.		0.2	442	169	0.39	0.24	
<b>Group B</b>							
11	male	4.7	1599	1523	7.51	5.27	unloaded
12	male	4.9	733	829	7.43	5.00	autologous DCs
13	female	4.6	1380	953	7.88	5.21	at weeks 0, 2,
14	female	4.0	1071	689	7.71	5.75	4, 6, and 8
Mean		4.6	1196	999	7.63	5.31	
s.d.		0.3	326	317	0.18	0.27	

FIG. 11